Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (2): 391-398.doi: 10.13481/j.1671-587X.20220216
• Research in basic medicine • Previous Articles Next Articles
Received:2021-07-12
Online:2022-03-28
Published:2022-05-10
Contact:
Qi LIU
E-mail:sbxz6329@163.com
CLC Number:
Qi LIU,Xin XU,Zhenggen WANG. Effect of calycosin on intestinal mucosal barrier function in cirrhosis rats and its mechanism[J].Journal of Jilin University(Medicine Edition), 2022, 48(2): 391-398.
Tab. 2
Levels of serum D-LA, DAO, and ET of rats in various groups"
| Group | D-LA[ρB/(mg·L-1)] | DAO[λB/(U·mL-1)] | ET[λB/(EU·mL-1)] |
|---|---|---|---|
| Control | 3.46±0.64 | 0.59±0.11 | 0.55±0.04 |
| Model | 13.38±1.47* | 2.49±0.45* | 0.98±0.05* |
| Calycosin | |||
| Low dose | 12.54±1.69 | 2.50±0.36 | 0.96±0.04 |
| High dose | 7.07±0.93△# | 1.30±0.26△# | 0.76±0.02△# |
| F | 70.057 | 40.386 | 354.622 |
| P | <0.01 | <0.01 | <0.01 |
Tab. 3
Levels of IL-1β、TNF-α and IL-6 in ileum tissue of rats in various groups [n=12,x±s, ρβ/(μg·L-1)]"
| Group | IL-1β | TNF-α | IL-6 |
|---|---|---|---|
| Control | 350.44±16.74 | 49.67±3.53 | 51.31±7.19 |
| Model | 635.68±19.87* | 157.19±4.59* | 123.98±10.40* |
| Calycosin | |||
| Low dose | 634.93±17.03 | 158.10±5.26 | 125.68±10.76 |
| High dose | 477.24±15.14△# | 89.52±5.40△# | 76.28±7.38△# |
| F | 764.723 | 630.948 | 195.623 |
| P | <0.01 | <0.01 | <0.01 |
Tab. 4
Expression levels of TLR4/NF-κB signaling pathway related proteins in ileum tissue of rats in various groups"
| Group | TLR-4 | NF-κB p65 | IκBα |
|---|---|---|---|
| Control | 0.47±0.13 | 0.25±0.10 | 0.63±0.09 |
| Model | 1.13±0.24* | 1.34±0.29* | 0.21±0.11* |
| Calycosin | |||
| Low dose | 1.09±0.20 | 1.31±0.27 | 0.22±0.10 |
| High dose | 0.64±0.18△# | 0.50±0.19△# | 0.49±0.05△# |
| F | 14.837 | 30.726 | 27.314 |
| P | <0.01 | <0.01 | <0.01 |
| 1 | BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives[J]. Gut, 2020, 69(6):1127-1138. |
| 2 | MEKURIA A N, ROUTLEDGE M N, GONG Y Y, et al. Aflatoxins as a risk factor for liver cirrhosis: a systematic review and meta-analysis[J]. BMC Pharmacol Toxicol, 2020, 21(1):1-8. |
| 3 | NISHIKAWA H, ENOMOTO H, NISHIGUCHI S, et al. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis[J]. Int J Mol Sci, 2020, 21(15):5254. |
| 4 | MEYER F, BANNERT K, WIESE M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis[J]. Int J Mol Sci, 2020, 21(15):5357. |
| 5 | WANG J W, PAN Y B, CAO Y Q, et al. Loganin alleviates LPS-activated intestinal epithelial inflammation by regulating TLR4/NF-κB and JAK/STAT3 signaling pathways[J]. Kaohsiung J Med Sci, 2020, 36(4):257-264. |
| 6 | 顾叶云, 胡莹杰, 徐 蕾, 等. 黄芪、水蛭有效组分对经脂多糖诱导增生的大鼠肾小球系膜细胞IκB、NF-κB、PDGF-BB表达的影响[J]. 中华中医药杂志, 2020, 35(2):866-868. |
| 7 | LI D Y, ZHAO L Q, LI Y X, et al. Gastro-protective effects of calycosin against precancerous lesions of gastric carcinoma in rats[J]. Drug Des Dev Ther, 2020, 14:2207-2219. |
| 8 | 宾文婷, 常加松, 吴剑平. 四氯化碳加乙醇复合法诱导肝硬化大鼠模型的建立及验证[J]. 中国组织工程研究, 2018, 22(20):3224-3229. |
| 9 | 高红杰. 参麦注射液对肝硬化大鼠模型肠道屏障功能的影响[J]. 川北医学院学报, 2020, 35(3):379-383. |
| 10 | 邓姗姗, 朱海涛, 陈 宇, 等. C57BL/6新生小鼠坏死性小肠结肠炎模型改建与评估[J]. 中华小儿外科杂志, 2018, 39(5):376-382. |
| 11 | HJORTH M, SVANBERG A, SJÖBERG D, et al. Liver cirrhosis turns life into an unpredictable roller coaster: A qualitative interview study[J]. J Clin Nurs, 2020, 29(23/24):4532-4543. |
| 12 | 陈 韬,宁 琴.终末期肝病合并感染诊治专家共识(2021年版)[J].临床肝胆病杂志,2022,38(2):304-310. |
| 13 | 周晓玲, 韦宛华, 陈 峭, 等. 麻黄升麻汤对肝硬化腹水并感染大鼠血清炎性因子的干预作用[J]. 中华中医药杂志, 2019, 34(4):1409-1414. |
| 14 | 周 乐, 赵晓莉, 狄留庆, 等. 大鼠在体单向肠灌流模型研究毛蕊异黄酮的吸收特征[J]. 南京中医药大学学报, 2014, 30(2):160-163. |
| 15 | 姚瀚勋, 李晓斌, 邱 晟, 等. 毛蕊异黄酮介导IκB/NF-κB信号通路对大鼠脑缺血再灌注损伤的保护作用[J]. 重庆医学, 2019, 48(1):11-14. |
| 16 | PLAZA-DÍAZ J, SOLÍS-URRA P, RODRÍGUEZ-RODRÍGUEZ F, et al. The gut barrier, intestinal microbiota, and liver disease: molecular mechanisms and strategies to manage[J]. Int J Mol Sci, 2020, 21(21):8351. |
| 17 | THEN E, LUND C, UHLENHOPP D J, et al. Cirrhosis is associated with worse outcomes in ischemic colitis: A nationwide retrospective study[J]. Gastroenterol Res, 2020, 13(6):253-259. |
| 18 | CHO Y E, KIM D K, SEO W, et al. Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress[J]. Hepatology, 2021, 73(6):2180-2195. |
| 19 | WOODHOUSE C, SINGANAYAGAM A, PATEL V C. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis[J]. Clin Med (Lond), 2020, 20(5):493-500. |
| 20 | 辜雪莲,李俊峰,毛小荣.非酒精性脂肪性肝病相关肝细胞癌的研究进展[J].临床肝胆病杂志,2022,38(1):196-200. |
| 21 | WANG J, LYU W T, ZHANG W, et al. Discovery of natural products capable of inducing porcine host defense peptide gene expression using cell-based high throughput screening[J]. J Animal Sci Biotechnol, 2021, 12(1):14. |
| 22 | SUN Z G, HU Y Z, WANG Y G, et al. BuPiHeWei decoction ameliorates 5-Fu-Induced intestinal mucosal injury in the rats by regulating the TLR-4/NF-κB signaling pathway[J]. Evid Based Complement Alternat Med, 2019, 2019:5673272. |
| 23 | GRAHAM D B, XAVIER R J. Pathway paradigms revealed from the genetics of inflammatory bowel disease[J]. Nature, 2020, 578(7796):527-539. |
| 24 | 张永虎, 张丹霞, 曾 良. 姜黄素通过TLR-4/NF-κB信号通路减轻脓毒症相关的急性肠损伤[J]. 实用医学杂志, 2020, 36(6):735-740. |
| 25 | ZHANG W H, SUN J K, SHEN X, et al. Effect of PA-MSAH preprocessing on the expression of TLR-4-NF-κB pathway and inflammatory factors in the intestinal tract of rats with septic shock[J]. Exp Ther Med, 2019, 17(4):2567-2574. |
| 26 | CHAO L, ZHENG P, XIA L, et al. Calycosin attenuates dextran sulfate sodium (DSS)-induced experimental colitis[J]. Iran J Basic Med Sci, 2017, 20(9):1056- 1062. |
